12.20Open12.20Pre Close0 Volume1 Open Interest115.00Strike Price0.00Turnover364.03%IV59.38%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry12.20Extrinsic Value100Contract SizeAmericanOptions Type-0.0857Delta0.0007Gamma20.74Leverage Ratio-0.8659Theta-0.0161Rho-1.78Eff Leverage0.0903Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet